{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T12:55:58Z","timestamp":1786366558928,"version":"build-2736575974"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.eplepsyres.2021.106592","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T00:14:25Z","timestamp":1613693665000},"page":"106592","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Efficacy of adjunctive cenobamate based on number of concomitant antiseizure medications, seizure frequency, and epilepsy duration at baseline: A post-hoc analysis of a randomized clinical study"],"prefix":"10.1016","volume":"172","author":[{"given":"William E","family":"Rosenfeld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2456-4439","authenticated-orcid":false,"given":"Arkady","family":"Nisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7060-6142","authenticated-orcid":false,"given":"Louis","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2021.106592_bib0005","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1528-1167.2010.02522.x","article-title":"Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009","volume":"51","author":"Berg","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2021.106592_bib0010","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1046\/j.1528-1157.2002.32201.x","article-title":"Seizure reduction and quality of life improvements in people with epilepsy","volume":"43","author":"Birbeck","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2021.106592_bib0015","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S1474-4422(12)70018-2","article-title":"Prognostic factors for time to treatment failure and time to 12 months of remission for patients with focal epilepsy: post-hoc, subgroup analyses of data from the SANAD trial","volume":"11","author":"Bonnett","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.eplepsyres.2021.106592_bib0020","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1212\/WNL.0b013e3182563b19","article-title":"Patterns of treatment response in newly diagnosed epilepsy","volume":"78","author":"Brodie","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2021.106592_bib0025","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","article-title":"Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study","volume":"75","author":"Chen","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.eplepsyres.2021.106592_bib0030","doi-asserted-by":"crossref","first-page":"e2311","DOI":"10.1212\/WNL.0000000000009530","article-title":"Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures","volume":"94","author":"Chung","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2021.106592_bib0035","first-page":"220","article-title":"Sudden unexpected death in epilepsy: risk factors, biomarkers, and prevention","volume":"139","author":"DeGiorgio","year":"2019","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.eplepsyres.2021.106592_bib0040","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1212\/WNL.0000000000001448","article-title":"Quality improvement in neurology: epilepsy update quality measurement set","volume":"84","author":"Fountain","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2021.106592_bib0045","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/epi.12074","article-title":"Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes","volume":"54","author":"Glauser","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2021.106592_bib0050","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.seizure.2016.11.022","article-title":"Drug development for refractory epilepsy: the past 25 years and beyond","volume":"44","author":"Golyala","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2021.106592_bib0055","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1001\/jamaneurol.2017.3069","article-title":"Questioning the effectiveness of newer antiseizure medications","volume":"75","author":"Hauser","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.eplepsyres.2021.106592_bib0060","doi-asserted-by":"crossref","first-page":"e2035","DOI":"10.1212\/WNL.0000000000006564","article-title":"Identification of patients who will not achieve seizure remission within 5 years on AEDs","volume":"91","author":"Hughes","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2021.106592_bib0065","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1528-1157.1981.tb06159.x","article-title":"Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the commission on classification and terminology of the international league against epilepsy","volume":"22","author":"International League Against Epilepsy","year":"1981","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2021.106592_bib0070","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/epi.13723","article-title":"The impact of seizures on epilepsy outcomes: a national, community-based survey","volume":"58","author":"Josephson","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2021.106592_bib0075","unstructured":"Klein, P., Krauss, G.L., Aboumatar, S., Kamin, M., 2019. Long-term efficacy and safety of adjunctive cenobamate in patients with uncontrolled focal seizures: open-label extension of a randomized clinical study [abstract]. American Epilepsy Society Annual Meeting, December 6-10, 2019, Baltimore, MD. Abstract 2.206."},{"key":"10.1016\/j.eplepsyres.2021.106592_bib0080","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1474-4422(19)30399-0","article-title":"Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial","volume":"19","author":"Krauss","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.eplepsyres.2021.106592_bib0085","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2021.106592_bib0090","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.yebeh.2014.05.031","article-title":"The consequences of refractory epilepsy and its treatment","volume":"37","author":"Laxer","year":"2014","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2021.106592_bib0095","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/ana.21064","article-title":"Results of treatment changes in patients with apparently drug-resistant chronic epilepsy","volume":"62","author":"Luciano","year":"2007","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.eplepsyres.2021.106592_bib0100","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejphar.2019.05.007","article-title":"Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons","volume":"855","author":"Nakamura","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2021.106592_bib0105","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1212\/WNL.0b013e31823ed0dd","article-title":"Comparative efficacy of combination drug therapy in refractory epilepsy","volume":"78","author":"Poolos","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2021.106592_bib0110","doi-asserted-by":"crossref","unstructured":"Rosenfeld, W.E., Abou-Khalil, B., Aboumatar, S., Bhatia, P., Biton, V., Krauss, G.L., Vossler, D.G., Wechsler, R., 2020. Dose adjustments to concomitant antiseizure medications: post-hoc analysis of a phase 3, open-label study of cenobamate for treatment of uncontrolled focal seizures [abstract]. American Epilepsy Society Annual Meeting, December 4-8, 2020. Abstract 336.","DOI":"10.1212\/WNL.96.15_supplement.1755"},{"key":"10.1016\/j.eplepsyres.2021.106592_bib0115","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1212\/01.wnl.0000286959.22040.6e","article-title":"Quantifying the response to antiepileptic drugs: effect of past treatment history","volume":"70","author":"Schiller","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2021.106592_bib0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173117","article-title":"Positive allosteric modulation of GABAA receptors by a novel antiepileptic drug cenobamate","volume":"879","author":"Sharma","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2021.106592_bib0125","series-title":"XCOPRI\u00ae (Cenobamate Tablets), for Oral Use, CV [prescribing Information]","author":"SK Life Science, Inc","year":"2020"},{"key":"10.1016\/j.eplepsyres.2021.106592_bib0130","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/epi.16525","article-title":"Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study","volume":"61","author":"Sperling","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2021.106592_bib0135","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/epi.13604","article-title":"The burden of premature mortality of epilepsy in high-income countries: a systematic review from the Mortality Task Force of the International League Against Epilepsy","volume":"58","author":"Thurman","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2021.106592_bib0140","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/14737175.2020.1707668","article-title":"The role of polytherapy in the management of epilepsy: suggestions for rational antiepileptic drug selection","volume":"20","author":"Verrotti","year":"2020","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.eplepsyres.2021.106592_bib0145","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.seizure.2006.02.012","article-title":"Cognitive effects of seizures","volume":"15","author":"Vingerhoets","year":"2006","journal-title":"Seizure"}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121121000450?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121121000450?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:44:38Z","timestamp":1760276678000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121121000450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":29,"alternative-id":["S0920121121000450"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2021.106592","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of adjunctive cenobamate based on number of concomitant antiseizure medications, seizure frequency, and epilepsy duration at baseline: A post-hoc analysis of a randomized clinical study","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2021.106592","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106592"}}